BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hornig N, Reinhardt K, Kermer V, Kontermann RE, Müller D. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy. Cancer Immunol Immunother 2013;62:1369-80. [PMID: 23715927 DOI: 10.1007/s00262-013-1441-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front Immunol 2020;11:147. [PMID: 32158444 DOI: 10.3389/fimmu.2020.00147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Schreiner J, Thommen DS, Herzig P, Bacac M, Klein C, Roller A, Belousov A, Levitsky V, Savic S, Moersig W, Uhlenbrock F, Heinzelmann-Schwarz VA, Umana P, Pisa P, von Bergwelt-Baildon M, Lardinois D, Müller P, Karanikas V, Zippelius A. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 2016;5:e1062969. [PMID: 27057429 DOI: 10.1080/2162402X.2015.1062969] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
3 Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol 2019;52:42-53. [PMID: 30991144 DOI: 10.1016/j.nbt.2019.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
4 [DOI: 10.1101/739987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hutmacher C, Neri D. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev 2019;141:67-91. [PMID: 30201522 DOI: 10.1016/j.addr.2018.09.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
6 Ahmad SM, Borch TH, Hansen M, Andersen MH. PD-L1-specific T cells. Cancer Immunol Immunother 2016;65:797-804. [DOI: 10.1007/s00262-015-1783-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
7 Mock J, Pellegrino C, Neri D. A universal reporter cell line for bioactivity evaluation of engineered cytokine products. Sci Rep 2020;10:3234. [PMID: 32094407 DOI: 10.1038/s41598-020-60182-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sapski S, Beha N, Kontermann RE, Müller D. Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response. Cancer Immunol Immunother 2020;69:2291-303. [PMID: 32504247 DOI: 10.1007/s00262-020-02624-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Aschmoneit N, Kocher K, Siegemund M, Lutz MS, Kühl L, Seifert O, Kontermann RE. Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). OncoImmunology 2022;11:2028961. [DOI: 10.1080/2162402x.2022.2028961] [Reference Citation Analysis]
10 Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology 2016;5:e1238540. [PMID: 27999756 DOI: 10.1080/2162402X.2016.1238540] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
11 Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 2016;40:24-35. [PMID: 26963133 DOI: 10.1016/j.coi.2016.02.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
12 Sapski S, Beha N, Kontermann R, Müller D. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. Oncoimmunology 2017;6:e1361594. [PMID: 29209565 DOI: 10.1080/2162402X.2017.1361594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Müller D. Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacol Ther 2015;154:57-66. [PMID: 26145167 DOI: 10.1016/j.pharmthera.2015.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
14 Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6:1359-1381. [PMID: 25682197 DOI: 10.18632/oncotarget.3204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
15 Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology 2018;7:e1471442. [PMID: 30228940 DOI: 10.1080/2162402X.2018.1471442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Müller D. Antibody–Cytokine Fusion Proteins for Cancer Immunotherapy: An Update on Recent Developments. BioDrugs 2014;28:123-31. [DOI: 10.1007/s40259-013-0069-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dahlén E, Veitonmäki N, Norlén P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother 2018;6:3-17. [PMID: 29998217 DOI: 10.1177/2515135518763280] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 23.8] [Reference Citation Analysis]
18 Warwas KM, Meyer M, Gonçalves M, Moldenhauer G, Bulbuc N, Knabe S, Luckner-Minden C, Ziegelmeier C, Heussel CP, Zörnig I, Jäger D, Momburg F. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Front Immunol 2021;12:719116. [PMID: 34484225 DOI: 10.3389/fimmu.2021.719116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]